Amylyx Pharmaceuticals (AMLX) Other Working Capital Changes (2022 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Other Working Capital Changes of -$327000.0 for Q1 2026, up 45.41% year-over-year from -$224882.9 in Q1 2025, and down 1521.74% quarter-over-quarter from $23000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$327000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 45.41% year-over-year to -$327000.0; the TTM figure through Mar 2026 stood at -$890000.0 (up 61.51% YoY), while the FY2025 annual figure was -$1.2 million, up 48.49% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$327000.0, down from $23000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $6.3 million in Q3 2023, with the low at -$4.4 million in Q2 2022.
- The 5-year median for Other Working Capital Changes is -$1.4 million (2026), against an average of -$335823.5.
- The sharpest annual moves came in 2023 and 2025: Other Working Capital Changes sank 16266.67% in 2023, then soared 103.92% in 2025.
- Amylyx Pharmaceuticals' Other Working Capital Changes stood at -$481000.0 in 2022, then fell by 10.6% to -$532000.0 in 2023, then slipped by 10.15% to -$586000.0 in 2024, then jumped by 103.92% to $23000.0 in 2025, then tumbled by 1521.74% to -$327000.0 in 2026.
- Business Quant data shows AMLX's Other Working Capital Changes at -$327000.0 in Q1 2026, $23000.0 in Q4 2025, and -$27000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -375,000.00 |
| Jun 30, 2026 | -375,000.00 |
| Jun 30, 2026 | -375,000.00 |
| Mar 31, 2026 | -327,000.00 |
| Mar 31, 2026 | -327,000.00 |
| Mar 31, 2026 | -327,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -559,000.00 |
| Jun 30, 2025 | -559,000.00 |
| Jun 30, 2025 | -559,000.00 |
| Mar 31, 2025 | -599,000.00 |
| Mar 31, 2025 | -599,000.00 |
| Mar 31, 2025 | -599,000.00 |
| Dec 31, 2024 | -586,000.00 |
| Dec 31, 2024 | -586,000.00 |